Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protease inhibitor with bortezomib and dexamethasone in bortezomib-refractory multiple myeloma
TCTR20211027004Phase 1Recruiting
- Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Faculty of Medicine Siriraj Hospital, Mahidol University. Primary endpoint: Safety. Started Mar 2024; status: recruiting.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on TCTR20211027004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211027004.